Tokyo, Japan
Tokyo, Japan

Time filter

Source Type

The present invention provides an aptamer binding to an autotaxin, which contains a nucleotide sequence represented by the formula: wherein W is A or U (provided uracil is optionally thymine), and which is the following (a) or (b):


The present invention provides an aptamer binding to an autotaxin, which contains a nucleotide sequence represented by the formula:GWAACAGGUUUUGCU (SEQ ID NO: 42)wherein W is A or U (provided uracil is optionally thymine), and which is the following (a) or (b):(a) an aptamer wherein, in the nucleotides contained in the aptamer,(i) the 2-position of the ribose of each pyrimidine nucleotide is a fluorine atom,(ii) the 2-position of the ribose of each purine nucleotide is a hydroxy group;(b) the aptamer of (a), wherein(i) the fluorine atom at the 2-position of the ribose of each pyrimidine nucleotide is independently unsubstituted, or substituted by an atom or group selected from the group consisting of a hydrogen atom, a hydroxy group and a methoxy group,(ii) the hydroxy group at the 2-position of the ribose of each purine nucleotide is independently unsubstituted, or substituted by an atom or group selected from the group consisting of a hydrogen atom, a methoxy group and a fluorine atom.


The present invention provides an aptamer that binds to an autotaxin, which contains a nucleotide sequence represented by the following formula (I):CGGAACC-N_(1)-GGTC(I)wherein N_(1) shows any of 3 to 11 nucleotides, and a utilization method thereof.


Patent
Ribomic Inc. | Date: 2017-02-01

Provided by the present invention are an aptamer having an inhibitory activity on FGF2; a complex containing an aptamer having a binding activity or an inhibitory activity on FGF2, and a functional substance (e.g., affinity substance, labeling substance, enzyme, drug delivery vehicle, or drug and the like); a medicament, diagnostic reagent or labeling agent containing an aptamer having a binding activity or an inhibitory activity on FGF2, or a complex containing said aptamer and a functional substance; and the like.


Patent
Ribomic Inc. and Otsuka Pharmaceutical Factory Inc. | Date: 2013-11-21

The present invention provides an aptamer binding to midkine and capable of forming a potential secondary structure represented by the formula (I): wherein


Patent
Ribomic Inc and Otsuka Pharmaceutical Factory Inc. | Date: 2012-04-18

Provided are an aptamer bound to chymase to inhibit activity of chymase; an aptamer containing a nucleotide sequence represented by X_(1)GAUAGAN_(1)N_(2)UAAX_(2) wherein X_(1) and X_(2) are the same or different and each is A or G, and N_(1) and N_(2) are the same or different and each is A, G, C, U or T; a complex containing the aptamer and a functional substance (e.g., affinity substance, labeling substance, enzyme, drug delivery medium, drug and the like); a pharmaceutical or a reagent containing the aptamer or complex; a detection and a purification methods of chymase using the aptamer or complex and the like.


Patent
Ribomic Inc and Otsuka Pharmaceutical Factory Inc. | Date: 2015-09-30

The present invention provides an aptamer binding to midkine and capable of forming a potential secondary structure represented by the formula (I):X1, X2, X5 and X6 are the same or different and each is one or two nucleotides selected from the group consisting of A, G, C, U and T, or a bond,X1 and X6, and X2 and X5 each form a Watson-Crick base pairs, andX3 and X4 are the same or different and each is a nucleotide selected from A, G, C, U and T.


Patent
Ribomic Inc | Date: 2014-08-06

The present invention provides an aptamer binding to NGF and capable of forming a potential secondary structure represented by the formula (I):N11 - N13, N21 - N23, N32 - N38 and N42 - N48 are the same or different and each is a bond or 1 or 2 nucleotides selected from the group consisting of A, G, C, U and T,N14, N24, N31, N41, N39 and N49 are the same or different and each is one nucleotide selected from the group consisting of A, G, C, U and T,N14 and N24, N31 and N41, and N39 and N49 each form a Watson-Crick base pair,N11-N12-N13-N14 and N21-N22-N23-N24 are nucleotide sequences capable of forming a stem structure in combination, andN31-N32-N33-N34-N35-N36-N37-N38-N39 and N41-N42-N43-N44-N45-N46-N47-N48-N49 are nucleotide sequences capable of forming a stem structure in combination.


Patent
Ribomic Inc | Date: 2012-12-19

Provided are an aptamer having an inhibitory activity on FGF2; a complex containing an aptamer having a binding activity or an inhibitory activity on FGF2, and a functional substance (e.g., affinity substance, labeling substance, enzyme, drug delivery vehicle, or drug and the like); a medicament, diagnostic reagent or label containing an aptamer having a binding activity or an inhibitory activity on FGF2, or a complex containing said aptamer and a functional substance; and the like.


Patent
Ribomic Inc and Shionogi & Co. | Date: 2013-01-30

Provided is a higher quality aptamer having a binding activity to NGF. An aptamer binding to NGF, which satisfies the following (1) and (2):(1) containing the sequence represented by UGAAARAAACC (SEQ ID NO: 64) or CGAAMRAAACU (SEQ ID NO: 65), and(2) having a base length of not more than 73.

Loading Ribomic Inc. collaborators
Loading Ribomic Inc. collaborators